Acetaminophen Hepatotoxicity: Current Management

Abstract

Mount Sinai Journal of Medicine: A Journal of Translational and Personalized MedicineVolume 76, Issue 1 p. 75-83 Special Features Acetaminophen Hepatotoxicity: Current Management Hui-Hui Tan MBBS, MRCP, Corresponding Author Hui-Hui Tan MBBS, MRCP [email protected] Division of Liver Diseases, Recanati-Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY Department of Gastroenterology and Hepatology, Singapore General Hospital, SingaporeDepartment of Gastroenterology and Hepatology, Singapore General Hospital, SingaporeSearch for more papers by this authorCharissa Y. Chang MD, Charissa Y. Chang MD Division of Liver Diseases, Recanati-Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NYSearch for more papers by this authorPaul Martin MD, Paul Martin MD Division of Hepatology, Centre for Liver Diseases, University of Miami School of Medicine. Miami, FLSearch for more papers by this author Hui-Hui Tan MBBS, MRCP, Corresponding Author Hui-Hui Tan MBBS, MRCP [email protected] Division of Liver Diseases, Recanati-Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY Department of Gastroenterology and Hepatology, Singapore General Hospital, SingaporeDepartment of Gastroenterology and Hepatology, Singapore General Hospital, SingaporeSearch for more papers by this authorCharissa Y. Chang MD, Charissa Y. Chang MD Division of Liver Diseases, Recanati-Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NYSearch for more papers by this authorPaul Martin MD, Paul Martin MD Division of Hepatology, Centre for Liver Diseases, University of Miami School of Medicine. Miami, FLSearch for more papers by this author First published: 23 January 2009 https://doi.org/10.1002/msj.20065Citations: 10AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J 1966; 2: 497– 499. 2Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179– 1197. 3Watson WA, Litovitz TL, Klein-Schwartz W, et al. 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2004; 22: 335– 404. 4Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology 2004; 40: 6– 9. 5Lee WM. Acetaminophen toxicity: changing perceptions on a social/medical issue. Hepatology 2007; 46: 966– 970. 6Blei AT. Brain edema in acute liver failure. Crit Care Clin 2008; 24: 99– 114, ix. 7Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364– 1372. 8Davern TJ II, James LP, Hinson JA, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006; 130: 687– 694. 9Khandelwal N, James LP, Simpson PM, et al. Identifying acetaminophen toxicity amongst indeterminate causes of acute liver failure [abstract]. Gastroenterology 2008; 134: SA– 752. 10Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet 1982; 7: 93– 107. 11Bizovi KE, Aks SE, Paloucek F, et al. Late increase in acetaminophen concentration after overdose of Tylenol Extended Relief. Ann Emerg Med 1996; 28: 549– 551. 12Cetaruk EW, Dart RC, Hurlbut KM, et al. Tylenol Extended Relief overdose. Ann Emerg Med 1997; 30: 104– 108. 13Tighe TV, Walter FG. Delayed toxic acetaminophen level after initial four hour nontoxic level. J Toxicol Clin Toxicol 1994; 32: 431– 434. 14Douglas DR, Sholar JB, Smilkstein MJ. A pharmacokinetic comparison of acetaminophen products (Tylenol Extended Relief vs regular Tylenol). Acad Emerg Med 1996; 3: 740– 744. 15Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005; 12: 133– 141. 16Lewis RK, Paloucek FP. Assessment and treatment of acetaminophen overdose. Clin Pharm 1991; 10: 765– 774. 17Prescott LF. Paracetamol overdosage. Pharmacological considerations and clinical management. Drugs 1983; 25: 290– 314. 18Makin AJ, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987–1993). Gastroenterology 1995; 109: 1907– 1916. 19Corcoran GB, Mitchell JR, Vaishnav YN, Horning EC. Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol 1980; 18: 536– 542. 20Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 2001; 31: 55– 138. 21Smilkstein MJ. Acetaminophen. In: LR Goldfrank, NE Flomenbaum, NA Lewin, eds. Goldfrank's Toxicologic Emergencies. Stamford, CT: Appleton & Lange 1998; 541. 22McBride PV, Rumack BH. Acetaminophen intoxication. Semin Dial 1992; 5: 292– 297. 23Suzuki A, Yuen NA, Papay JI, et al. An Aers database evaluation of influence of co-medications on acetaminophen-associated liver injury. Gastroenterology 2008; 134: SA– 758. 24Polson J, Orsulak PJ, Wians F, et al. Elevated bilirubin may cause false positive acetaminophen levels in hepatitis patients [abstract]. Hepatology 2004; 40: 496A. 25Bertholf RL, Johannsen LM, Bazooband A, Mansouri V. False-positive acetaminophen results in a hyperbilirubinemic patient. Clin Chem 2003; 49: 695– 698. 26Beuhler MC, Curry SC. False positive acetaminophen levels associated with hyperbilirubinemia. Clin Toxicol (Phila) 2005; 43: 167– 170. 27Read RB, Tredger JM, Williams R. Analysis of factors responsible for continuing mortality after paracetamol overdose. Hum Toxicol 1986; 5: 201– 206. 28Ambre J, Alexander M. Liver toxicity after acetaminophen ingestion. Inadequacy of the dose estimate as an index of risk. JAMA 1977; 238: 500– 501. 29Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975; 55: 871– 876. 30Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002; 40: 3– 20. 31Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319: 1557– 1562. 32Wootton FT, Lee WM. Acetaminophen hepatotoxicity in the alcoholic. South Med J 1990; 83: 1047– 1049. 33Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 272: 1845– 1850. 34Rumack BH, Holtzman J, Chase HP. Hepatic drug metabolism and protein malnutrition. J Pharmacol Exp Ther 1973; 186: 441– 446. 35Dart RC, Kuffner EK, Rumack BH. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther 2000; 7: 123– 134. 36Prescott LF. Paracetamol, alcohol and the liver. Br J Clin Pharmacol 2000; 49: 291– 301. 37Kuffner EK, Dart RC, Bogdan GM, et al. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001; 161: 2247– 2252. 38Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction? Am J Ther 2000; 7: 99– 114. 39Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy 2007; 27: 1219– 1230. 40Shayiq RM, Roberts DW, Rothstein K, et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology 1999; 29: 451– 463. 41Schiodt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997; 337: 1112– 1117. 42Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003; 23: 217– 226. 43Mutimer DJ, Ayres RC, Neuberger JM, et al. Serious paracetamol poisoning and the results of liver transplantation. Gut 1994; 35: 809– 814. 44Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria. J Hepatol 1997; 26: 62– 68. 45O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439– 445. 46Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002; 359: 558– 563. 47Pereira LM, Langley PG, Hayllar KM, et al. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators. Gut 1992; 33: 98– 102. 48Mitchell I, Bihari D, Chang R, et al. Earlier identification of patients at risk from acetaminophen-induced acute liver failure. Crit Care Med 1998; 26: 279– 284. 49Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002; 36: 659– 665. 50Chung PY, Sitrin MD, Te HS. Serum phosphorus levels predict clinical outcome in fulminant hepatic failure. Liver Transpl 2003; 9: 248– 253. 51Ng KL, Davidson JS, Bathgate AJ. Serum phosphate is not a reliable early predictor of outcome in paracetamol induced hepatotoxicity. Liver Transpl 2004; 10: 158– 159. 52Gregory B, Odina CV, Moe O, et al. Abnormal urinary excretion of phosphate is responsible for hypophosphotaemia in acute liver failure [abstract]. Gastroenterology 2008; 134: SA– 800. 53Schmidt LE, Larsen FS. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007; 45: 789– 796. 54Schmidt LE, Dalhoff K. Hyperamylasaemia and acute pancreatitis in paracetamol poisoning. Aliment Pharmacol Ther 2004; 20: 173– 179. 55Schiodt FV, Bondesen S, Tygstrup N, Christensen E. Prediction of hepatic encephalopathy in paracetamol overdose: a prospective and validated study. Scand J Gastroenterol 1999; 34: 723– 728. 56Harrison PM, O'Grady JG, Keays RT, et al. Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ 1990; 301: 964– 966. 57Lin JH, Levy G. Sulfate depletion after acetaminophen administration and replenishment by infusion of sodium sulfate or N-acetylcysteine in rats. Biochem Pharmacol 1981; 30: 2723– 2725. 58Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J 1979; 2: 1097– 1100. 59Smilkstein MJ, Bronstein AC, Linden C, et al. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991; 20: 1058– 1063. 60Cuzzocrea S, Costantino G, Mazzon E, Caputi AP. Protective effect of N-acetylcysteine on multiple organ failure induced by zymosan in the rat. Crit Care Med 1999; 27: 1524– 1532. 61Bajt ML, Knight TR, Lemasters JJ, Jaeschke H. Acetaminophen-induced oxidant stress and cell injury in cultured mouse hepatocytes: protection by N-acetyl cysteine. Toxicol Sci 2004; 80: 343– 349. 62Rowden AK, Norvell J, Eldridge DL, Kirk MA. Acetaminophen poisoning. Clin Lab Med 2006; 26: 49– 65, viii. 63Wendon JA, Harrison PM, Keays R, Williams R. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology 1994; 19: 1407– 1413. 64Spies CD, Reinhart K, Witt I, et al. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit Care Med 1994; 22: 1738– 1746. 65Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991; 324: 1852– 1857. 66Devlin J, Ellis AE, McPeake J, et al. N-acetylcysteine improves indocyanine green extraction and oxygen transport during hepatic dysfunction. Crit Care Med 1997; 25: 236– 242. 67Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990; 335: 1572– 1573. 68Keays R, Harrison PM, Wendon JA, et al. R. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991; 303: 1026– 1029. 69Prescott LF, Illingworth RN, Critchley JA, Proudfoot AT. Intravenous N-acetylcysteine: still the treatment of choice for paracetamol poisoning. Br Med J 1980; 280: 46– 47. 70Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning? J Toxicol Clin Toxicol 1999; 37: 759– 767. 71Yip L, Dart RC, Hurlbut KM. Intravenous administration of oral N-acetylcysteine. Crit Care Med 1998; 26: 40– 43. 72Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003; 31: 299– 305. 73Green R, Grierson R, Sitar DS, Tenenbein M. How long after drug ingestion is activated charcoal still effective? J Toxicol Clin Toxicol 2001; 39: 601– 605. 74Underhill TJ, Greene MK, Dove AF. A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Arch Emerg Med 1990; 7: 148– 154. 75Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2006; CD003328. 76Slattery JT, McRorie TI, Reynolds R, et al. Lack of effect of cimetidine on acetaminophen disposition in humans. Clin Pharmacol Ther 1989; 46: 591– 597. 77Burkhart KK, Janco N, Kulig KW, Rumack BH. Cimetidine as adjunctive treatment for acetaminophen overdose. Hum Exp Toxicol 1995; 14: 299– 304. 78Marbury TC, Wang LH, Lee CS. Hemodialysis of acetaminophen in uremic patients. Int J Artif Organs 1980; 3: 263– 266. 79Matthew H. Acute acetaminophen poisoning. Clin Toxicol 1973; 6: 9– 11. 80Prescott LF. Haemodialysis in paracetomol self-poisoning. Lancet 1972; 2: 652. 81N-acetylcysteine in the treatment of acetaminophen overdose. N Engl J Med 1989; 320: 1417– 1418. 82Williams R. Hepatic encephalopathy. J R Coll Physicians Lond 1973; 8: 63– 74. 83Gazzard BG, Willson RA, Weston MJ, et al. Charcoal haemoperfusion for paracetamol overdose. Br J Clin Pharmacol 1974; 1: 271. 84O'Grady JG, Gimson AE, O'Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94: 1186– 1192. 85Detry O, Arkadopoulos N, Ting P, et al. Clinical use of a bioartificial liver in the treatment of acetaminophen-induced fulminant hepatic failure. Am Surg 1999; 65: 934– 938. 86Ash SR, Caldwell CA, Singer GG, et al. Treatment of acetaminophen-induced hepatitis and fulminant hepatic failure with extracorporeal sorbent-based devices. Adv Ren Replace Ther 2002; 9: 42– 53. 87O'Grady JG, Wendon J, Tan KC, et al. Liver transplantation after paracetamol overdose. BMJ 1991; 303: 221– 223. 88Bernal W, Wendon J, Rela M, et al. Use and outcome of liver transplantation in acetaminophen-induced acute liver failure. Hepatology 1998; 27: 1050– 1055. 89Sheen CL, Dillon JF, Bateman DN, et al. Paracetamol pack size restriction: the impact on paracetamol poisoning and the over-the-counter supply of paracetamol, aspirin and ibuprofen. Pharmacoepidemiol Drug Saf 2002; 11: 329– 331. 90Hawton K, Townsend E, Deeks J, et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ 2001; 322: 1203– 1207. 91Hawton K, Simkin S, Deeks J, et al. UK legislation on analgesic packs: before and after study of long term effect on poisonings. BMJ 2004; 329: 1076. 92Wilkinson S, Taylor G, Templeton L, et al. Admissions to hospital for deliberate self-harm in England 1995–2000: an analysis of hospital episode statistics. J Public Health Med 2002; 24: 179– 183. Citing Literature Volume76, Issue1February 2009Pages 75-83 ReferencesRelatedInformation